[ad_1]
Faron Pharmaceuticals Ltd. (LON: FARN) Managing Director Markku Jalkanen tells Andrew Scott of Proactive London that he will target more patients with advanced colorectal cancer as part of the Phase I / II study of his Clevegen immunotherapy drug.
One of the patients currently enrolled in the trial presents the most common form of colorectal cancer, called MSI-low, and experienced a "significant narrowing" of lung metastases.
The stage of expansion of the cohort is scheduled for later this year, once the optimal dose has been identified.
Source link
